BIO-TECHNE Corp

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

TECH$72.82-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Earnings and Comprehensive Income

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

AND COMPREHENSIVE INCOME

(in thousands, except per share data)


	Quarter Ended
· · September 30,
· · 2025 · · 2024
Net sales		$286,555	$289,458
Cost of sales		98,443	106,441
Gross margin		188,112	183,017

Operating expenses:
Selling, general and administrative		116,213	119,161
Research and development		24,241	23,869
Total operating expenses		140,454	143,030
Operating income		47,658	39,987

Other income (expense)		333	184
Earnings before income taxes		47,991	40,171
Income taxes		9,806	6,571
Net earnings		$38,185	$33,600
Other comprehensive income (loss):
Foreign currency translation income (loss)		(2,850)	21,256
Unrealized gains (losses) on derivative instruments		(1,665)	(3,027)
Other comprehensive income (loss)		(4,515)	18,229
Comprehensive income		$33,670	$51,829

Earnings per share:
Basic		$0.25	$0.21
Diluted		$0.24	$0.21

Weighted average common shares outstanding:
Basic		155,464	158,531
Diluted		156,362	161,115

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.